Inventor
ROTH JACK A
US34 patents
⚠️ This page may combine multiple inventors who share the name “ROTH JACK A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV TEXAS
31 patentsUS6143290ANov 7, 2000
Tumor regression by adenovirus expression of wild-type p53
UNIV TEXAS130 citations99
US6410010B1Jun 25, 2002
Recombinant P53 adenovirus compositions
UNIV TEXAS76 citations97
US6069134AMay 30, 2000
Methods and compositions comprising DNA damaging agents and p53
UNIV TEXAS278 citations97
US5747469AMay 5, 1998
Methods and compositions comprising DNA damaging agents and p53
UNIV TEXAS150 citations97
US6740320B1May 25, 2004
Recombinant P53 adenovirus methods and compositions
UNIV TEXAS27 citations96
US6511847B1Jan 28, 2003
Recombinant p53 adenovirus methods and compositions
UNIV TEXAS46 citations96
US5958892ASep 28, 1999
2-methoxyestradiol-induced apoptosis in cancer cells
UNIV TEXAS48 citations96
US6110744AAug 29, 2000
Diminishing viral gene expression by promoter replacement
UNIV TEXAS43 citations94
US6017524AJan 25, 2000
Inhibiting the growth p53 deficient tumor cells by administering the p53 gene
UNIV TEXAS43 citations94
US6410029B1Jun 25, 2002
2-methoxyestradiol-induced apoptosis in cancer cells
UNIV TEXAS34 citations92
US5637456AJun 10, 1997
Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
UNIV TEXAS30 citations92
US7109179B2Sep 19, 2006
Methods and compositions comprising DNA damaging agents and p53
UNIV TEXAS15 citations91
US6797702B1Sep 28, 2004
Methods and compositions comprising DNA damaging agents and P53
UNIV TEXAS22 citations91
US6627189B1Sep 30, 2003
Inhibition of cellular proliferation using ras antisense molecules
UNIV TEXAS28 citations89
US6482803B1Nov 19, 2002
Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
UNIV TEXAS35 citations89
US7163925B1Jan 16, 2007
p16 expression constructs and their application in cancer therapy
UNIV TEXAS12 citations82
US6805858B1Oct 19, 2004
Methods for the administration of adenovirus p53
UNIV TEXAS10 citations82
US6630344B1Oct 7, 2003
Diminishing viral gene expression by promoter replacement
UNIV TEXAS12 citations81
US6899870B1May 31, 2005
Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
UNIV TEXAS16 citations78
US6905873B1Jun 14, 2005
Recombinant p53 adenovirus methods and compositions
UNIV TEXAS4 citations74
US6830749B2Dec 14, 2004
Recombinant P53 adenovirus methods and compositions
UNIV TEXAS3 citations74
US11278592B2Mar 22, 2022
Methods and compositions for TUSC2 immunotherapy
UNIV TEXAS2 citations73
US7244617B2Jul 17, 2007
Diminishing viral gene expression by promoter replacement
UNIV TEXAS5 citations72
US6998117B1Feb 14, 2006
Cancer treatment with retroviral vectors comprising wild-type p53
UNIV TEXAS9 citations72
US6251871B1Jun 26, 2001
P16 expression constructs and their application in cancer therapy
UNIV TEXAS13 citations72
US6436700B1Aug 20, 2002
Anti-sense p21 k-ras
UNIV TEXAS10 citations70
US7033750B2Apr 25, 2006
Recombinant P53 adenovirus methods and compositions
UNIV TEXAS2 citations63
US6133416AOct 17, 2000
Inhibition of cell growth by an anti-proliferative factor
UNIV TEXAS8 citations63
US12485159B2Dec 2, 2025
Methods and compositions for TUSC2 immunotherapy
UNIV TEXAS0 citations62
US7423015B1Sep 9, 2008
Antihelminthic drugs as a treatment for hyperproliferative diseases
UNIV TEXAS2 citations60
US8859727B2Oct 14, 2014
Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
UNIV TEXAS2 citations58